FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2154955103> ?p ?o ?g. }

• W2154955103 endingPage "1143" @default.
• W2154955103 startingPage "1138" @default.
• W2154955103 abstract "BackgroundThe goal of this article is to present clinical and patency results of endovascular treatment of nonmalignant, iliocaval venous obstructive disease and to discuss the evolution of technical details.MethodsFrom November 1995 to June 2004, 44 patients (female-male ratio, 3.9:1; left-right lower limb ratio, 8.6:1; median age, 42 years; range, 21-80 years) had treatment for chronic disabling obstructive venous insufficiency with iliocaval stenosis or occlusion. The clinical class of CEAP was 2 in 11 limbs, 3 in 31, 4 in 4, 5 in 1, and 6 in 1; etiology was primary in 32 patients, secondary in 10, and congenital in 2. Anatomic involvement included superficial veins in 16 patients and perforator veins in 11. Obstruction was associated with superficial reflux in 4 patients, deep reflux in 13, and both in 13. Ten patients had occlusion. All procedures were performed in the operating room with perioperative angiography and angioplasty with or without self-expanding stent implantation. Venous clinical severity and disability scores were obtained before and after treatment. Patency and restenosis were evaluated by duplex Doppler ultrasonography.ResultsNo perioperative death or pulmonary embolism occurred. The technical success rate was 95.5% (two recanalization failures), and two (4.5%) perioperative stent migrations occurred. One early thrombosis (2.4%) was treated by thrombectomy and creation of an arteriovenous fistula. One late death and one thrombosis occurred. Restenoses were found in five patients and were all treated successfully (four needed iterative stenting). Median follow-up was 27 months (range, 2-103 months). Median venous clinical severity score improved from 8.5 to 2, and median venous disability score improved from 2 to 0. Cumulative primary, assisted primary, and secondary patency rates of the venous segments at 36 months were 73%, 88%, and 90%, respectively, in intention to treat. The survival rate was 100% at 12 months and 97.3% at 60 months.ConclusionsEndovascular treatment of benign iliocaval occlusive disease is a safe and efficient minimally invasive technique with good mid-term patency rates. Moreover, it improves cases with obstruction only, as well as cases with associated reflux and obstruction. Primary stenting should always be performed by using self-expanding stents deployed under general anesthesia to avoid lumbar pain. In case of failure, the endovascular procedure does not preclude further surgical reconstruction. The goal of this article is to present clinical and patency results of endovascular treatment of nonmalignant, iliocaval venous obstructive disease and to discuss the evolution of technical details. From November 1995 to June 2004, 44 patients (female-male ratio, 3.9:1; left-right lower limb ratio, 8.6:1; median age, 42 years; range, 21-80 years) had treatment for chronic disabling obstructive venous insufficiency with iliocaval stenosis or occlusion. The clinical class of CEAP was 2 in 11 limbs, 3 in 31, 4 in 4, 5 in 1, and 6 in 1; etiology was primary in 32 patients, secondary in 10, and congenital in 2. Anatomic involvement included superficial veins in 16 patients and perforator veins in 11. Obstruction was associated with superficial reflux in 4 patients, deep reflux in 13, and both in 13. Ten patients had occlusion. All procedures were performed in the operating room with perioperative angiography and angioplasty with or without self-expanding stent implantation. Venous clinical severity and disability scores were obtained before and after treatment. Patency and restenosis were evaluated by duplex Doppler ultrasonography. No perioperative death or pulmonary embolism occurred. The technical success rate was 95.5% (two recanalization failures), and two (4.5%) perioperative stent migrations occurred. One early thrombosis (2.4%) was treated by thrombectomy and creation of an arteriovenous fistula. One late death and one thrombosis occurred. Restenoses were found in five patients and were all treated successfully (four needed iterative stenting). Median follow-up was 27 months (range, 2-103 months). Median venous clinical severity score improved from 8.5 to 2, and median venous disability score improved from 2 to 0. Cumulative primary, assisted primary, and secondary patency rates of the venous segments at 36 months were 73%, 88%, and 90%, respectively, in intention to treat. The survival rate was 100% at 12 months and 97.3% at 60 months. Endovascular treatment of benign iliocaval occlusive disease is a safe and efficient minimally invasive technique with good mid-term patency rates. Moreover, it improves cases with obstruction only, as well as cases with associated reflux and obstruction. Primary stenting should always be performed by using self-expanding stents deployed under general anesthesia to avoid lumbar pain. In case of failure, the endovascular procedure does not preclude further surgical reconstruction." @default.
• W2154955103 created "2016-06-24" @default.
• W2154955103 creator A5001018165 @default.
• W2154955103 creator A5032089303 @default.
• W2154955103 creator A5052804040 @default.
• W2154955103 creator A5062547325 @default.
• W2154955103 creator A5064648729 @default.
• W2154955103 creator A5074391606 @default.
• W2154955103 creator A5084960130 @default.
• W2154955103 date "2005-12-01" @default.
• W2154955103 modified "2023-10-18" @default.
• W2154955103 title "Mid-term results of endovascular treatment for symptomatic chronic nonmalignant iliocaval venous occlusive disease" @default.
• W2154955103 cites W1976024392 @default.
• W2154955103 cites W1991475780 @default.
• W2154955103 cites W2000164201 @default.
• W2154955103 cites W2025125738 @default.
• W2154955103 cites W2041736996 @default.
• W2154955103 cites W2060321368 @default.
• W2154955103 cites W2075185710 @default.
• W2154955103 cites W2081859350 @default.
• W2154955103 cites W2082674414 @default.
• W2154955103 cites W2106842269 @default.
• W2154955103 cites W2154944020 @default.
• W2154955103 cites W2158113397 @default.
• W2154955103 cites W2159301242 @default.
• W2154955103 cites W2163998944 @default.
• W2154955103 cites W4249702215 @default.
• W2154955103 cites W4255821514 @default.
• W2154955103 doi "https://doi.org/10.1016/j.jvs.2005.08.012" @default.
• W2154955103 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16376204" @default.
• W2154955103 hasPublicationYear "2005" @default.
• W2154955103 type Work @default.
• W2154955103 sameAs 2154955103 @default.
• W2154955103 citedByCount "142" @default.
• W2154955103 countsByYear W21549551032012 @default.
• W2154955103 countsByYear W21549551032013 @default.
• W2154955103 countsByYear W21549551032014 @default.
• W2154955103 countsByYear W21549551032015 @default.
• W2154955103 countsByYear W21549551032016 @default.
• W2154955103 countsByYear W21549551032017 @default.
• W2154955103 countsByYear W21549551032018 @default.
• W2154955103 countsByYear W21549551032019 @default.
• W2154955103 countsByYear W21549551032020 @default.
• W2154955103 countsByYear W21549551032021 @default.
• W2154955103 countsByYear W21549551032022 @default.
• W2154955103 countsByYear W21549551032023 @default.
• W2154955103 crossrefType "journal-article" @default.
• W2154955103 hasAuthorship W2154955103A5001018165 @default.
• W2154955103 hasAuthorship W2154955103A5032089303 @default.
• W2154955103 hasAuthorship W2154955103A5052804040 @default.
• W2154955103 hasAuthorship W2154955103A5062547325 @default.
• W2154955103 hasAuthorship W2154955103A5064648729 @default.
• W2154955103 hasAuthorship W2154955103A5074391606 @default.
• W2154955103 hasAuthorship W2154955103A5084960130 @default.
• W2154955103 hasBestOaLocation W21549551031 @default.
• W2154955103 hasConcept C126322002 @default.
• W2154955103 hasConcept C126838900 @default.
• W2154955103 hasConcept C141071460 @default.
• W2154955103 hasConcept C2776268601 @default.
• W2154955103 hasConcept C2778269268 @default.
• W2154955103 hasConcept C2778283817 @default.
• W2154955103 hasConcept C2778583881 @default.
• W2154955103 hasConcept C2779134260 @default.
• W2154955103 hasConcept C2780007028 @default.
• W2154955103 hasConcept C2780011451 @default.
• W2154955103 hasConcept C2780326628 @default.
• W2154955103 hasConcept C2780643987 @default.
• W2154955103 hasConcept C2780868729 @default.
• W2154955103 hasConcept C31174226 @default.
• W2154955103 hasConcept C43270747 @default.
• W2154955103 hasConcept C71924100 @default.
• W2154955103 hasConceptScore W2154955103C126322002 @default.
• W2154955103 hasConceptScore W2154955103C126838900 @default.
• W2154955103 hasConceptScore W2154955103C141071460 @default.
• W2154955103 hasConceptScore W2154955103C2776268601 @default.
• W2154955103 hasConceptScore W2154955103C2778269268 @default.
• W2154955103 hasConceptScore W2154955103C2778283817 @default.
• W2154955103 hasConceptScore W2154955103C2778583881 @default.
• W2154955103 hasConceptScore W2154955103C2779134260 @default.
• W2154955103 hasConceptScore W2154955103C2780007028 @default.
• W2154955103 hasConceptScore W2154955103C2780011451 @default.
• W2154955103 hasConceptScore W2154955103C2780326628 @default.
• W2154955103 hasConceptScore W2154955103C2780643987 @default.
• W2154955103 hasConceptScore W2154955103C2780868729 @default.
• W2154955103 hasConceptScore W2154955103C31174226 @default.
• W2154955103 hasConceptScore W2154955103C43270747 @default.
• W2154955103 hasConceptScore W2154955103C71924100 @default.
• W2154955103 hasIssue "6" @default.
• W2154955103 hasLocation W21549551031 @default.
• W2154955103 hasLocation W21549551032 @default.
• W2154955103 hasOpenAccess W2154955103 @default.
• W2154955103 hasPrimaryLocation W21549551031 @default.
• W2154955103 hasRelatedWork W141524600 @default.
• W2154955103 hasRelatedWork W1971526940 @default.
• W2154955103 hasRelatedWork W2023737161 @default.
• W2154955103 hasRelatedWork W2049871566 @default.
• W2154955103 hasRelatedWork W2112061508 @default.
• W2154955103 hasRelatedWork W2137338049 @default.

• next